• Explore /
  • Poster
  • / A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.

A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.

Abstract Poster

Authors

Rachel Freedman

Rachel A. Freedman

Dana-Farber Cancer Institute, Boston, MA

Rachel A. Freedman , Ines Maria Vaz Duarte Luis , William Thomas Barry , Ian E. Krop , Nikhil Wagle , Alarice Lowe , Sarah Galler , Jessica Sohl , Steven J. Isakoff , Nadine M. Tung , Eric P. Winer , Nancy U. Lin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT01912963

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS668)

DOI

10.1200/jco.2014.32.15_suppl.tps668

Abstract #

TPS668

Poster Bd #

124A

Abstract Disclosures

Similar Posters

First Author: Nicholas Patrick McAndrew

First Author: Ines Maria Vaz Duarte Luis

First Author: Zhonghui Ou

First Author: Santiago Escrivá